PPD will provide clinical management services in key therapeutic areas from this new location in Japan. The office strengthens PPD’s operations in the country, where it has worked regionally and through a subcontractor, said PPD.
Fred Eshelman, CEO of PPD, said: “Japan offers competitive timelines for site startup and patient enrollment, and the government is making major improvements to streamline drug development, bringing Japan’s regulatory timelines more in line with the rest of the world.
“With our clients increasingly including Japan in their global drug development programs, having a base of operations in Tokyo will enable us to better meet their growing needs.”